Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
J Immunother Cancer
.
2022 Jan;10(1):e004272.
doi: 10.1136/jitc-2021-004272.
Authors
Alexander Eggermont
1
,
Michal Kicinski
2
,
Stefan Suciu
2
Affiliations
1
Research Directorate Princess Maxima Center & Cancer Medicine University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands alexander.eggermont@prinsesmaximacentrum.nl.
2
Department of Statistics, EORTC, Brussels, Belgium.
PMID:
35042824
PMCID:
PMC8768906
DOI:
10.1136/jitc-2021-004272
No abstract available
Keywords:
adjuvants; autoimmunity; immunologic; immunotherapy; melanoma.
Publication types
Letter
Comment
MeSH terms
Adjuvants, Immunologic
Humans
Melanoma*
Skin Neoplasms*
Substances
Adjuvants, Immunologic